David Tobin Harrington

David Tobin Harrington

Auto-generated profile, based on publicly available information

David Tobin Harrington

Brown University School of Medicine, Providence, RI

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in Journal of Nuclear Cardiology
Verified
Journal Article
Closed access
PDF file
AGAnthony S. Gemignani
Anthony S. Gemignani
SMStephan G. Muhlebach
Stephan G. Muhlebach
BABrian G. Abbott
Brian G. Abbott
GRG. Dean Roye
G. Dean Roye
DHDavid T. Harrington
David T. Harrington
JAJames A. Arrighi
James A. Arrighi

21 June 2023 in Journal of Burn Care & Research
Verified
Journal Article
Open access
PDF file
KGKevin Eliezer Galicia
Kevin Eliezer Galicia
CTCallie M Thompson
Callie M Thompson
ALAislinn E Lewis
Aislinn E Lewis
CJCara Joyce
Cara Joyce
DHDavid M Hill
David M Hill
JKJohn C Kubasiak
John C Kubasiak
The Burn Care Quality Platform (BCQP) consolidates data previously collected from the National Burn Repository and the Burn Quality Improvement Program into a single registry. Its data elements and their associated definitions are tailored to create consistency across other national trauma registries, namely the National Trauma Data Bank implemented by the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP). The BCQP now includes 103 participating burn centers and has captured data from 375,000 total patients as of 2021. With 12,000 patients entered under the current data dictionary, the BCQP represents the largest registry of its kind. On behalf of the American Burn Association Research Committee, the aim of this whitepaper is to provide a succinct overview of the BCQP, showcasing its unique features, strengths, limitations, and relevant statistical considerations. This whitepaper will highlight the resources available to the burn research community and offer insight on proper study design when preparing to conduct a large data set investigation for burn care. All recommendations herein were formulated through the consensus of a multidisciplinary committee and based on the available scientific evidence.

1 September 2023 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Open access
SHSharon Henry
Sharon Henry
SMSteven Mapula
Steven Mapula
MGMark Grevious
Mark Grevious
KFKevin Foster
Kevin Foster
HPHerbert Phelan
Herbert Phelan
JMJoseph A. Molnar
Joseph A. Molnar
BACKGROUND: Traumatic insults, infection, and surgical procedures can leave skin defects that are not amenable to primary closure. Split-thickness skin grafting (STSG) is frequently used to achieve closure of these wounds. Although effective, STSG can be associated with donor site morbidity, compounding the burden of illness in patients undergoing soft tissue reconstruction procedures. With an expansion ratio of 1:80, autologous skin cell suspension (ASCS) has been demonstrated to significantly decrease donor skin requirements compared with traditional STSG in burn injuries. We hypothesized that the clinical performance of ASCS would be similar for soft tissue reconstruction of nonburn wounds. METHODS: A multicenter, within-patient, evaluator-blinded, randomized-controlled trial was conducted of 65 patients with acute, nonthermal, full-thickness skin defects requiring autografting. For each patient, two treatment areas were randomly assigned to concurrently receive a predefined standard-of-care meshed STSG (control) or ASCS + more widely meshed STSG (ASCS+STSG). Coprimary endpoints were noninferiority of ASCS+STSG for complete treatment area closure by Week 8, and superiority for relative reduction in donor skin area. RESULTS: At 8 weeks, complete closure was observed for 58% of control areas compared with 65% of ASCS+STSG areas (p = 0.005), establishing noninferiority of ASCS+STSG. On average, 27.4% less donor skin was required with ASCS+ STSG, establishing superiority over control (p < 0.001). Clinical healing (≥95% reepithelialization) was achieved in 87% and 85% of Control and ASCS+STSG areas, respectively, at 8 weeks. The treatment approaches had similar long-term scarring outcomes and safety profiles, with no unanticipated events and no serious ASCS device-related events. CONCLUSION: ASCS+STSG represents a clinically effective and safe solution to reduce the amount of skin required to achieve definitive closure of full-thickness defects without compromising healing, scarring, or safety outcomes. This can lead to reduced donor site morbidity and potentially decreased cost associated with patient care. Clincaltrials.gov identifier: NCT04091672 LEVEL OF EVIDENCE: Therapeutic/Care Management; Level I.

1 January 2002 in AIHA Journal
Verified
Journal Article
Closed access
PSPeter F. Scholz
Peter F. Scholz
BMBarbara L. Materna
Barbara L. Materna
DHDavid Harrington
David Harrington
CUConnie Uratsu
Connie Uratsu
The California Painters Project was a 2-year intervention research project aimed at preventing lead poisoning among a group of residential and commercial painters in San Francisco, Calif. As part of this project 12 contractors invited project staff to conduct employee exposure monitoring. Twenty-five full-shift samples were collected, with 8-hr TWA results ranging from 0.8 to 550 µg/m3 (arithmetic mean: 57 µg/m3). Six of the 25 samples (24%) were above the Occupational Safety and Health Administration (OSHA) permissible exposure limit; all of these involved dry manual sanding or uncontrolled power sanding. Fifty-eight 30-minute task-specific samples also were collected. The arithmetic mean concentration results for heat gun use, wet sanding, and open flame burning were all under 10 µg/m3; the mean concentration for HEPA-exhausted power sanding was 33 µg/m3; dry manual scraping, 71 µg/m3; dry manual sanding, 420 µg/m3; and uncontrolled power sanding, 580 µg/m3. Analysis and modeling based on the 30-min results for dry manual sanding and uncontrolled power sanding indicate that painters' full-shift exposures often exceed 500 µg/m3 and the OSHA assigned level of protection for a half-mask air-purifying respirator. These results are cause for concern because both of these surface preparation methods are widely performed wearing half-mask respirators. The data show that HEPA-exhausted power sanding reduces paint dust exposure levels by approximately 80 to 90%. These tools should be more widely promoted as a safer alternative work method.

1 January 2007 in Cancer Investigation
Verified
Journal Article
Closed access
DEDevon Evans
Devon Evans
TMThomas Miner
Thomas Miner
DIDavid Iannitti
David Iannitti
PAPaul Akerman
Paul Akerman
DCDennis Cruff
Dennis Cruff
HSHoward Safran
Howard Safran
A Phase I investigation of docetaxel, carboplatin, and capecitabine at our institution demonstrated the safety and tolerability of this regimen in patients with metastatic esophagogastric cancer. The objectives of this Phase II study were to determine the response rate, toxicity, and survival for patients with metastatic esophagogastric cancer treated with this regimen. Chemotherapy naïve patients with metastatic esophageal or gastric cancer received a regimen comprised of docetaxel 40 mg/m(2), days 1 and 8, carboplatin AUC = 2, Days 1 and 8, and capecitabine 2000 mg/m(2), Days 1-10 in 21-Day cycles. Patients were treated until disease progression or unacceptable toxicity. Twenty-five patients were treated with a median of 4 cycles of chemotherapy. Twelve of 25 patients (48 percent) had a Grade 3/4 toxicity. There were no Grade 4 nonhematologic toxicities, and 1 patient (4 percent) had neutropenic fever. There were 3 complete responses, and 9 partial responses, for an overall response rate of 48 percent. The median survival was 8 months (95% confidence interval, 5.5-13 months), and the 1-year survival was 36 percent. Weekly docetaxel and carboplatin with capecitabine was an easily administered outpatient regimen. The response rate and 1-year survival were similar to more complex regimens. Future trials may investigate the substitution of carboplatin with more active agents.

30 March 2022 in Journal of Surgical Education
Verified
Journal Article
Closed access
MBMelissa E. Brunsvold
Melissa E. Brunsvold
TFThomas F. Fise
Thomas F. Fise
MHMark Hickey
Mark Hickey
BJBenjamin T. Jarman
Benjamin T. Jarman
AJAmit R.T. Joshi
Amit R.T. Joshi
DHDavid T. Harrington
David T. Harrington